Business Context and Reporting Period
Company: McKesson Corporation (MCK)
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2020
Reporting Period: Supplemental historical financial information provided for fiscal quarters ended June 30, 2019, through June 30, 2020, and fiscal years ended March 31, 2019, and 2020.
Effective July 1, 2020, McKesson realigned its operating structure to reflect a focus on innovative healthcare solutions. The company will report results in four new reportable segments on a retrospective basis starting in the second quarter of fiscal 2021: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Key Financial Metrics
This filing serves to provide supplemental historical segment data conforming to the new structure. The document does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. It explicitly states that the segment changes did not impact previously issued consolidated financial statements or earnings per common share.
Material Changes
- Segment Restructuring: The company transitioned from its previous reporting structure to four new segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and RxTS.
- Change Healthcare Separation: The company completed the separation from its investment in Change Healthcare LLC (Change Healthcare JV) during the fourth quarter of fiscal 2020. Consequently, financial results for the JV are included in the "Other" category for retrospective periods presented.
- Retrospective Application: Historical financial information has been restated to align with the new segment definitions to assist investors in understanding the impact of the changes.
Guidance, Outlook, and Management Commentary
Management commentary focuses on the strategic rationale for the restructuring, emphasizing the delivery of new and innovative solutions to evolving healthcare needs. The new segments reflect how the chief operating decision maker allocates resources and assesses performance.
- U.S. Pharmaceutical: Distributes drugs and provides practice management and clinical solutions to pharmacies and oncology practices.
- International: Covers operations in Europe (13 countries) and Canada, including distribution, specialty pharmacy, and retail (Rexall Health).
- Medical-Surgical Solutions: Provides supply distribution and logistics to healthcare providers across the U.S.
- RxTS: Integrates CoverMyMeds, RelayHealth, RxCrossroads, and High Volume Solutions to connect pharmacies, providers, and payers.
The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the description of the completed Change Healthcare separation.
Investor Verification Checklist
- Review Exhibit 99.1 included in the filing for the specific supplemental historical financial data by the new reportable segments.
- Verify the impact of the Change Healthcare JV separation on the "Other" segment results in retrospective periods.
- Confirm that previously issued consolidated financial statements and earnings per share remain unchanged despite the segment reclassification.
- Check subsequent filings for the first official quarter of results reported under the new four-segment structure (Q2 Fiscal 2021).